TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing Smoking Treatment Programs for Lighter Smokers
Brief Summary: The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment completion and highest rates of abstinence.


Options:
A: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
B: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1: Bup+MM; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Medication Management, Drug: placebo patch | Arm Label: 2 Bup+Mayo; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Mayo Counseling, Drug: placebo patch | Arm Label: 3 Patch+MM; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal system, Behavioral: Medication Management, Drug: placebo bupropion | Arm Label: 4 Patch+Mayo; Type: EXPERIMENTAL; Interventions: Drug: nicotine transdermal system, Behavioral: Mayo Counseling, Drug: placebo bupropion | Intervention Type: DRUG; Name: nicotine transdermal system; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: BEHAVIORAL; Name: Medication Management; Assigned to Arm(s): 1: Bup+MM, 3 Patch+MM | Intervention Type: BEHAVIORAL; Name: Mayo Counseling; Assigned to Arm(s): 2 Bup+Mayo, 4 Patch+Mayo | Intervention Type: DRUG; Name: placebo patch; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: DRUG; Name: placebo bupropion; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo
D: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)
Brief Summary: The purpose of this study is to compare 5-year mortality rates in diabetic individuals with multivessel coronary artery disease (CAD) who undergo either coronary artery bypass grafting (CABG) surgery or percutaneous coronary stenting.


Options:
A: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin
C: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Coronary Artery Bypass Graft; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Coronary Artery Bypass Graft | Arm Label: Percutaneous Coronary Intervention; Type: EXPERIMENTAL; Interventions: Device: Percutaneous Coronary Intervention | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass Graft; Assigned to Arm(s): Coronary Artery Bypass Graft | Intervention Type: DEVICE; Name: Percutaneous Coronary Intervention; Assigned to Arm(s): Percutaneous Coronary Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy
Brief Summary: The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.


Options:
A: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vildagliptin Placebo | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sitagliptin 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Sitagliptin, Drug: Comparator: Pioglitazone, Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo, Drug: Comparator: Pioglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Comparator: Sitagliptin; Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Comparator: Pioglitazone; Assigned to Arm(s): Placebo, Sitagliptin 100 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo, Sitagliptin 100 mg
C: Arm Label: Vildagliptin 50 mg qd + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin 50 mg bid + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin placebo + pioglitazone 45 mg qd; Type: PLACEBO_COMPARATOR; Interventions: Drug: pioglitazone, Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd, Vildagliptin placebo + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Vildagliptin placebo + pioglitazone 45 mg qd
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior
Brief Summary: This study will determine the efficacy and safety of citalopram compared to placebo in the treatment of children with autism.


Options:
A: Arm Label: Sertraline Liquid Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline Liquid Placebo | Arm Label: Sertraline Active Medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Sertraline Liquid Placebo; Assigned to Arm(s): Sertraline Liquid Placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Sertraline Active Medication
B: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior
Brief Summary: This study will determine the efficacy and safety of citalopram compared to placebo in the treatment of children with autism.


Options:
A: Arm Label: Placebo for AChEI and Choline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Indistinguishable placebo tablets, matching both donepezil and choline | Arm Label: AChEI and Choline; Type: EXPERIMENTAL; Interventions: Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements | Intervention Type: DRUG; Name: Acetyl-Choline Esterase Inhibitors and Choline supplements; Assigned to Arm(s): AChEI and Choline | Intervention Type: DRUG; Name: Indistinguishable placebo tablets, matching both donepezil and choline; Assigned to Arm(s): Placebo for AChEI and Choline
B: Arm Label: Arm 1: 12 weeks of study drug then 15 weeks of placebo; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL, Drug: Placebo | Arm Label: Arm 3: 15 weeks of placebo then 12 weeks of study drug; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL, Drug: Placebo | Arm Label: Arm 3: 27 weeks of study drug; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL | Intervention Type: DRUG; Name: Oral cannabidiol 100mg/mL; Assigned to Arm(s): Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug, Arm 3: 27 weeks of study drug | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior
Brief Summary: This study will determine the efficacy and safety of citalopram compared to placebo in the treatment of children with autism.


Options:
A: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Extended-release guanfacine; Type: EXPERIMENTAL; Interventions: Drug: extended-release guanfacine | Arm Label: Inactive placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Inactive placebo | Intervention Type: DRUG; Name: extended-release guanfacine; Assigned to Arm(s): Extended-release guanfacine
C: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amitriptyline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Post Tibial Nerve Stimulation Group (PTNS); Type: EXPERIMENTAL; Interventions: Device: NURO TM | Arm Label: Sham Group; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: NURO TM; Assigned to Arm(s): Post Tibial Nerve Stimulation Group (PTNS) | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham Group
C: Arm Label: Pentosan polysulfate sodium 100 mg once a day; Type: EXPERIMENTAL; Interventions: Drug: Pentosan polysulfate sodium 100 mg | Arm Label: Pentosan polysulfate sodium 100 mg three times a day; Type: EXPERIMENTAL; Interventions: Drug: Pentosan polysulfate sodium 100 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pentosan polysulfate sodium 100 mg; Assigned to Arm(s): Pentosan polysulfate sodium 100 mg three times a day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pentosan polysulfate sodium 100 mg; Assigned to Arm(s): Pentosan polysulfate sodium 100 mg once a day
D: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK0431 Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Brief Summary: The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Arm Label: Sitagliptin 100 mg/100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin (MK0431), Drug: Metformin - Rescue | Arm Label: Sitagliptin 200 mg/200 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin, Drug: Metformin - Rescue | Arm Label: Placebo/Sitagliptin 100 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin - Rescue | Arm Label: Placebo/Sitagliptin 200 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin - Rescue | Intervention Type: DRUG; Name: Sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg/100 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin 200 mg/200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin 200 mg | Intervention Type: DRUG; Name: Metformin - Rescue; Assigned to Arm(s): Placebo/Sitagliptin 100 mg, Placebo/Sitagliptin 200 mg, Sitagliptin 100 mg/100 mg, Sitagliptin 200 mg/200 mg
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
Brief Summary: This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS. The study will enroll approximately 435 subjects at up to 60 sites in the United States and Canada.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1
B: Arm Label: Threshold estimates; Type: EXPERIMENTAL; Interventions: Other: descriptive case-scenarios | Arm Label: Alternative threshold estimates; Type: ACTIVE_COMPARATOR; Interventions: Other: descriptive case-scenarios | Intervention Type: OTHER; Name: descriptive case-scenarios; Assigned to Arm(s): Alternative threshold estimates, Threshold estimates
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Laquinimod 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod 0.6 mg, Laquinimod 1.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Laquinimod 0.6 mg
D: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
Brief Summary: This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS. The study will enroll approximately 435 subjects at up to 60 sites in the United States and Canada.


Options:
A: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A
D: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
Brief Summary: This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS. The study will enroll approximately 435 subjects at up to 60 sites in the United States and Canada.


Options:
A: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (control procedure) | Arm Label: Epidural injection of etanercept; Type: EXPERIMENTAL; Interventions: Drug: epidural injection of etanercept | Intervention Type: DRUG; Name: epidural injection of etanercept; Assigned to Arm(s): Epidural injection of etanercept | Intervention Type: DRUG; Name: placebo (control procedure); Assigned to Arm(s): 1
D: Arm Label: Golimumab (CNTO 148) with Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: MTX | Arm Label: Infliximab with MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX, Drug: Infliximab | Arm Label: Placebo with MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: MTX, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX) | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX), Infliximab with MTX, Placebo with MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with MTX | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab with MTX

Answer: B